SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Bridgetech Holdings International Inc. (OTC: BGTH - News), a company focused on maximizing the potential of emerging healthcare products and services in the U.S. and Asian markets, announced today that they have acquired the Asian rights to two reformulated cancer therapeutics. Bridgetech will have the right to manufacture and distribute these products throughout the Peoples Republic of China (PRC), Hong Kong, Macau and Taiwan. Bridgetech will also receive rights to two promising antibiotics and first right of refusal for Asian rights on future oncology therapeutics.
